Alfacalcidol

Generic Name: Alfacalcidol

Brand Names: One-alpha

Drug Type: Small Molecule

Chemical Formula: C_₂₇H_₄₄O_₂

CAS Number: 41294-56-8

Unique Ingredient Identifier: URQ2517572

Background: Alfacalcidol, or 1-alpha-hydroxycholecalciferol or 1-alpha-hydroxyvitamin D3, is a non-endogenous analogue of vitamin D. It plays an essential function in calcium homeostasis and bone metabolism. Alfacaldisol is activated by the enzyme 25-hydroxylase in the liver to mediate its effects in the body, or most importantly, the kidneys and bones. The pharmacologi...

Indication: Alfacalcidol is indicated in adult patients with chronic renal failure for the management of hypocalcemia, secondary hyperparathyroidism, or osteodystrophy.
...

Associated Conditions: Hypocalcemia, Hypophosphatemic Rickets, Nutritional Rickets, Osteodystrophy, Osteomalacia, Rickets, Secondary Hyperparathyroidism (SHPT), Hypophosphatemic osteomalacia

Associated Therapies: -

Clinical Trials

Effect of Alfacalcidol on Muscle Function in Osteoporosis Patients

Phase 4

Not yet recruiting

Conditions: Sarcopenia

Interventions: Drug: placebo
Drug: alfacalcidol
Drug: Denosumab

First Posted Date: 2024-02-22

Last Posted Date: 2024-02-22

Lead Sponsor: Yonsei University

Target Recruit Count: 340

Registration Number: NCT06272227

Locations: 🇰🇷
Division of Endocrinology, Department of internal Medicine, Yonsei University College of Medicine, Severance Hospital, Seoul, Korea, Republic of

Effect of Alfacalcidol to Respiratory Infection and Immune Response of Indonesian Elderly

Phase 4

Conditions: Elderly Infection
Frail Elderly Syndrome

Interventions: Drug: Alfacalcidol

First Posted Date: 2017-09-26

Last Posted Date: 2017-09-26

Lead Sponsor: Indonesia University

Target Recruit Count: 110

Registration Number: NCT03292744

Locations: 🇮🇩
Cipto Mangunkusumo National Hospital, Jakarta, Indonesia

Active Vitamin D And Reduced Dose Prednisolone for Treatment in Minimal Change Nephropathy

Phase 4

Active, not recruiting

Conditions: Minimal Change Disease
Nephrotic Syndrome

Interventions: Drug: Prednisolone
Drug: Alfacalcidol

First Posted Date: 2017-07-07

Last Posted Date: 2024-02-20

Lead Sponsor: University of Aarhus

Target Recruit Count: 71

Registration Number: NCT03210688

Locations: 🇩🇰
Aarhus University Hospital, Aarhus, Denmark
🇩🇰
Regional Hospital Viborg, Viborg, Denmark

Clinical Study of Treating Type 2 Diabetic Nephropathy With Alfacalcidol and Irbesartan

Phase 4

Completed

Conditions: Type 2 Diabetic Nephropathy

Interventions: Drug: Alfacalcidol
Drug: Irbesartan

First Posted Date: 2017-05-10

Last Posted Date: 2019-10-10

Lead Sponsor: The Third Xiangya Hospital of Central South University

Target Recruit Count: 60

Registration Number: NCT03147677

Locations: 🇨🇳
Hunan Chenzhou NO.1 People's Hospital, Chenzhou, Hunan, China
🇨🇳
The Third Xiangya Hospital of Central South University, Changsha, Hunan, China
🇨🇳
Hunan Yiyang Central Hospital, Yiyang, Hunan, China

Effectiveness of Oral Alfacalcidol for Secondary Hyperparathyroidism in Chronic Hemodialysis Patients.

Not Applicable

Completed

Conditions: Alfacalcidol, Secondary Hyperparathyroidism, Hemodialysis

Interventions: Drug: Alfacalcidol

First Posted Date: 2016-09-09

Last Posted Date: 2017-05-31

Lead Sponsor: Phramongkutklao College of Medicine and Hospital

Target Recruit Count: 502

Registration Number: NCT02895061

Recombinant Human rhPTH(1-34) VS Association Alfacalcidol/Hydrochlorothiazide in Severe Primary Hypoparathyroidism

Phase 2

Completed

Conditions: Autosomal Dominant Hypocalcemia OR Primary Hypoparathyroidism Related to Other Cause But Complicated by Hypercalciuria Under Treatment

Interventions: Drug: Teriparatide
Drug: Thiazide
Drug: Potassium sparing diuretic
Drug: Alfacalcidol

First Posted Date: 2016-07-07

Last Posted Date: 2021-06-28

Lead Sponsor: Assistance Publique - Hôpitaux de Paris

Target Recruit Count: 16

Registration Number: NCT02824718

Locations: 🇫🇷
AP-HP Hopital Europeen Georges Pompidou, Paris, France

The Effect of Alfacalcidol on Muscle Strength in Elderly Indonesian Women : A Randomized Controlled Trial

Phase 3

Completed

Conditions: Muscle Weakness

Interventions: Drug: alfacalcidol

First Posted Date: 2014-12-30

Last Posted Date: 2014-12-30

Lead Sponsor: Indonesia University

Target Recruit Count: 122

Registration Number: NCT02327091

Locations: 🇮🇩
Division of Geriatrics, Department of Internal Medicine, University of Indonesia, Jakarta Pusat, Jakarta, Indonesia

Eldecalcitol for GLucocorticoid Induced OsteopoRosIs Versus Alfacalcidol

Not Applicable

Conditions: Osteoporosis

Interventions: Drug: Alfacalcidol
Drug: Eldecalcitol

First Posted Date: 2013-11-01

Last Posted Date: 2014-08-06

Lead Sponsor: e-GLORIA trial Protocol Review Committee

Target Recruit Count: 400

Registration Number: NCT01974167

Locations: 🇯🇵
Nara Hospital Kinki University Faculty of Medicine, Ikoma, Nara, Japan

The Effect of Inactive and Active Vitamin D on Serum Sclerostin/dickkopf1 Levels

Phase 4

Conditions: Osteoporosis

Interventions: Drug: Placebo
Drug: Cholecalciferol
Drug: Alfacalcidol
Drug: Calcitriol

First Posted Date: 2013-01-10

Last Posted Date: 2013-01-10

Lead Sponsor: Seoul National University Hospital

Target Recruit Count: 88

Registration Number: NCT01765010

Locations: 🇰🇷
Seoul National University Medical School, Seoul, Korea, Republic of

Fall Prevention by Alfacalcidol and Training

Phase 4

Withdrawn

Conditions: Accidental Falls
Chronic Renal Insufficiency
Aged

First Posted Date: 2007-06-07

Last Posted Date: 2011-07-21

Lead Sponsor: Ruhr University of Bochum

Target Recruit Count: 484

Registration Number: NCT00483275

Locations: 🇩🇪
Klinik für Altersmedizin und Frührehabilitation, Marienhospital, Ruhr-Universität Bochum, Herne, NRW, Germany

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy